135,422 Shares in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Purchased by Wealthfront Advisers LLC

Wealthfront Advisers LLC acquired a new stake in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 135,422 shares of the biopharmaceutical company's stock, valued at approximately $2,826,000. Wealthfront Advisers LLC owned 0.11% of Catalyst Pharmaceuticals as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also recently bought and sold shares of the company. abrdn plc bought a new position in shares of Catalyst Pharmaceuticals during the fourth quarter worth $10,115,000. Raymond James Financial Inc. acquired a new stake in Catalyst Pharmaceuticals during the 4th quarter worth $6,887,000. Jane Street Group LLC lifted its holdings in Catalyst Pharmaceuticals by 245.4% during the third quarter. Jane Street Group LLC now owns 401,908 shares of the biopharmaceutical company's stock worth $7,990,000 after acquiring an additional 285,564 shares in the last quarter. Walleye Capital LLC bought a new position in Catalyst Pharmaceuticals during the third quarter worth about $4,936,000. Finally, Pacer Advisors Inc. grew its stake in Catalyst Pharmaceuticals by 5.4% in the fourth quarter. Pacer Advisors Inc. now owns 2,955,508 shares of the biopharmaceutical company's stock valued at $61,681,000 after acquiring an additional 151,495 shares during the period. Institutional investors and hedge funds own 79.22% of the company's stock.

Catalyst Pharmaceuticals Stock Performance

Catalyst Pharmaceuticals stock traded up $0.79 during mid-day trading on Monday, reaching $21.81. The company's stock had a trading volume of 1,202,370 shares, compared to its average volume of 1,261,541. Catalyst Pharmaceuticals, Inc. has a 12 month low of $14.47 and a 12 month high of $24.64. The business's 50 day simple moving average is $22.26 and its 200 day simple moving average is $21.53. The company has a market capitalization of $2.65 billion, a price-to-earnings ratio of 18.48, a price-to-earnings-growth ratio of 3.31 and a beta of 0.84.

Remove Ads

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on the company. Baird R W raised Catalyst Pharmaceuticals to a "strong-buy" rating in a research report on Monday, February 3rd. Bank of America restated a "buy" rating and set a $30.00 target price on shares of Catalyst Pharmaceuticals in a report on Thursday, January 9th. StockNews.com upgraded shares of Catalyst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Friday, February 28th. HC Wainwright restated a "buy" rating and set a $35.00 price objective on shares of Catalyst Pharmaceuticals in a report on Friday, February 28th. Finally, Stephens reaffirmed an "overweight" rating and issued a $33.00 price objective on shares of Catalyst Pharmaceuticals in a research report on Thursday, February 27th. Eight equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Buy" and an average price target of $32.50.

Insider Transactions at Catalyst Pharmaceuticals

In related news, insider Brian Elsbernd sold 62,975 shares of the business's stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $22.98, for a total transaction of $1,447,165.50. Following the transaction, the insider now directly owns 188,564 shares in the company, valued at approximately $4,333,200.72. The trade was a 25.04 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Gary Ingenito sold 44,904 shares of the stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $22.09, for a total transaction of $991,929.36. Following the completion of the sale, the insider now owns 68,873 shares of the company's stock, valued at approximately $1,521,404.57. This represents a 39.47 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 11.00% of the company's stock.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.